iBio (IBIO) “announced the Company will host a conference call on Tuesday, March 17, at 4 p.m. ET. The conference call will address iBio’s strategic pipeline expansion into pulmonary hypertension associated with heart failure with preserved ejection fraction and will include a presentation from Martin Brenner, DVM, Ph.D., iBio’s Chief Executive Officer and Chief Scientific Officer, and Cory Schwartz, Ph.D., the Company’s Director of Research and Early Development.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IBIO:
- Buy Rating on iBio Driven by Promising IBIO-610 Obesity Data and Favorable Risk-Reward Profile
- iBio Highlights IBIO-610 Obesity and Cardiometabolic Potential
- iBio announces new preclinical data from study evaluating IBIO-610
- iBio initiated with a Buy at JonesResearch
- Ibio Ends At-The-Market Equity Offering Program